What $MSLP & $BMTL have in common? $BMTL has a much lower a/s = 100m
http://www.marketwire.com/press-release/forme...600711.htm
http://investing.businessweek.com/research/st...s%2C%20Inc .
Former Assistant U.S. Surgeon General Roscoe M. Moore, Jr., DVM, PhD, MPH Joins the BioMedical Technology Solutions Scientific Advisory Board
ENGLEWOOD, CO--(Marketwire - Dec 20, 2011) - BioMedical Technology Solutions Holdings, Inc. ("BMTS," "the Company") (OTCBB: BMTL ) announced today the addition of former Assistant U.S. Surgeon General Roscoe M. Moore, Jr., DVM, PhD, MPH to its Scientific Advisory Board.
"We are honored and excited that Dr. Roscoe Moore will be joining our esteemed Scientific Advisory Board. Dr. Moore's experience and expertise with both national and international public health issues make him an outstanding addition to our team. Dr. Moore has an extensive background within the FDA and U.S. Public Health Services that will allow him to lead our efforts in the implementation of the Demolizer II where it is needed most. We look forward to a long and productive relationship with Dr. Moore," stated Jonathan Bricken, CEO of BMTS.
The Demolizer II eliminates the need to store and frequently handle biomedical waste by converting infectious biomedical waste into noninfectious material. BMTS has initiated a campaign to place Demolizer II machines in clinics, hospitals, care facilities and other venues that regularly utilize medical syringes which could harbor infectious diseases such as HIV and Hepatitis C.
BMTS recently began its outreach efforts to HIV clinicians and care and service providers at the 2011 United States Conference on AIDS (USCA) that took place this past November in Chicago, Illinois. BMTS exhibited the Demolizer II alongside the National Association of People with AIDS (NAPWA), demonstrating its effectiveness in curbing the spread of HIV.
"I am pleased to join BioMedical Technology Solutions as a member of their Scientific Advisory Board. The unsafe disposal of contaminated syringes has long been a means of proliferation of HIV through avoidable needlestick injuries due to improper disposal. Eliminating this risk factor can be one of the less challenging HIV prevention efforts by placing Demolizer II machines in clinics and hospitals worldwide," said Dr. Moore.
About BioMedical Technology Solutions Holdings, Inc.
BioMedical Technology Solutions Holdings, Inc., located in Englewood, Colorado, sells and rents the Demolizer® II through its wholly owned subsidiary BioMedical Technology Solutions, Inc. BMTS' patented Demolizer® Technology converts infectious biomedical waste into non-infectious material. BMTS' products provide biomedical waste treatment solutions for the over 1,000,000 low to medium volume medical waste generators in the US and a global market five times larger than the US. For more information, visit http://www.bmtscorp.com/ or call 866-525-2687.
About the Demolizer® II
The Demolizer® II is the GREEN alternative to biomedical waste disposal. The device is the only patented, portable, and self-contained system able to process both sharps and typical red bag biomedical waste onsite. The processed waste is rendered sterile and discarded as common trash eliminating up to 100% of the cost associated with its disposal. The Demolizer® II meets or exceeds all EPA and CDC guidelines and is approved or meets treatment requirements in 48 states after review by 80 governmental agencies. The device uses no chemicals or liquids, plugs into a normal outlet through a surge protector, and automatically records and prints state required documentation. The Demolizer® II provides a safer, more environmentally GREEN method for biomedical waste disposal.
Safe Harbor for Forward Looking Statements
The statements contained in this press release may include certain projections and forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve a number of risks and uncertainties. Such statements reflect the Company's current views with respect to future events and financial performance. No assurances can be given however, that these events will occur or that such expectations will be achieved and that actual results could differ materially from those described. Actual results of future operations of BioMedical Technology Solutions Holdings, Inc. may differ materially from those indicated by these forward looking statements as a result of various important factors.
Contact Information
-
Contact:
Gex "Jay" F. Richardson
BMTL President and Chairman
(954) 275-3309
